aripiprazole / Generic mfg. - LARVOL DELTA

Real-world Pharmacovigilance Study of Drug-induced Diabetes Insipidus from the FAERS Database. (PubMed, Endocr Connect) - "Lithium (n = 114, Information Component at the 95% lower credibility interval [IC025] = 6.12) and dexmedetomidine (n = 105, IC025 = 6.79) were identified as the most frequently reported drugs and showed the strongest association with DI. Several drugs, such as aripiprazole, letrozole, tigecycline, and dapagliflozin, were found to have unexpected potential associations with DI. This study provides a comprehensive overview of drug-induced DI based on real-world data. It highlights the importance of monitoring patients for DI when using certain medications, particularly high-risk nervous system drugs and antineoplastic agents."

Adverse events • Journal • Real-world evidence • Metabolic Disorders • Oncology

Rapid treatment initiation in patients with schizophrenia: evaluation of the clinical and functional outcomes of the two-injection start regimen of aripiprazole once-monthly. (PubMed, Int J Psychiatry Clin Pract) - "The TIS regimen of AOM 400 mg demonstrated rapid symptomatic and functional improvement with good tolerability. Further large-scale prospective studies are warranted."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Neuropathic Pruritus as a Precursor to Delusional Parasitosis in Multiple Sclerosis: A Proposed Clinical Trajectory and Case Report. (PubMed, Cureus) - "This case illustrates a possible clinical progression from neuropathic pruritus to delusional parasitosis in MS. The findings underscore the importance of early recognition to potentially prevent progression, as well as the need for coordinated care involving primary care, neurology, dermatology, and psychiatry."

Journal • CNS Disorders • Cognitive Disorders • Depression • Dermatology • Mood Disorders • Multiple Sclerosis • Pruritus • Psychiatry

Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of CYP2D6 phenotype on metabolic abnormalities. (PubMed, Am J Health Syst Pharm) - "This study suggests that the incidence of metabolic abnormalities beyond LDL may not be higher in CYP2D6 poor metabolizers compared to normal metabolizers. Further research is needed to investigate clinically meaningful outcomes in relation to CYP2D6 and aripiprazole."

Journal • Retrospective data • CNS Disorders • Dyslipidemia • Mental Retardation • Psychiatry

Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists. (PubMed, Ment Health Clin) - "Aripiprazole, brexpiprazole, and cariprazine have a unique pharmacology as demonstrated by their high affinity to the dopamine type-2 receptor (ie, D2 receptor). Some partial agonists may be less preferred in particular patient scenarios based on their demonstrated clinical efficacy. Three illustrative patient cases highlight clinical pearls related to the safe and effective use of antipsychotic polypharmacy involving partial agonist antipsychotics."

Journal • Anesthesia • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry

Dopaminergic tone inhibits spontaneous glutamate release and augments homeostatic synaptic plasticity. (PubMed, Mol Psychiatry) - "Notably, chronic antagonism of both D1 and D2 receptors using selective antagonists, as well as long-term treatment with first- and second-generation antipsychotics haloperidol, chlorpromazine, olanzapine, clozapine, and aripiprazole, promoted robust synaptic upscaling. These findings reveal a novel mechanism of action for antipsychotic medications and suggest that antipsychotics do not solely act on counteracting hyperdopaminergia, but also tune glutamatergic neurotransmission by activating homeostatic plasticity mechanisms."

Journal • CNS Disorders

The effect of switching antipsychotics to aripiprazole versus paliperidone on weight/cardiometabolic parameters: 18-month follow-up findings from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). (PubMed, Eur Neuropsychopharmacol) - "In conclusion, switching to aripiprazole or paliperidone did not prevent AiWG and LAIs showed no metabolic advantage relative to oral counterparts. The association between smoking and increased weight gain suggests smoking may represent a modifiable risk factor, warranting further investigation of smoking cessation as a potential intervention in AiWG management."

Journal • CNS Disorders • Psychiatry • Schizophrenia • Tobacco Cessation

Trajectory analysis of BMI increase induced by second-generation antipsychotics in first-episode schizophrenia: a secondary analysis based on CNFEST***. (PubMed, Schizophrenia (Heidelb)) - P=N/A | "After quality control, a total of 361 drug-naïve FES patients treated with olanzapine, risperidone, or aripiprazole were included. A high-risk subgroup (LBRI) with rapid early weight gain was identified, driven by olanzapine use, shorter DUP, and lower educational attainment. These findings advocate for dynamic risk stratification and early preventive interventions in vulnerable FES patients (Trial Registration: This trial was registered at ClinicalTrials.gov (Identifier: NCT01057849) on January 26, 2010)."

Journal • CNS Disorders • Psychiatry • Schizophrenia

A case of Klinefelter syndrome presenting with an acute psychotic episode after COVID-19 infection. (PubMed, PCN Rep) - "Psychotic symptoms improved in about 2 months with an antipsychotic, aripiprazole. To our knowledge, this is the first report of a KS patient who acutely developed a psychotic disorder after COVID-19. Vulnerability to psychotic conditions of KS likely manifests as an acute psychotic episode facilitated by the neurotropic effects of COVID-19."

Journal • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Genetic Disorders • Infectious Disease • Mental Retardation • Novel Coronavirus Disease • Psychiatry • Schizophrenia

Shared Psychotic Disorder in the Digital Age: A Case Series of Virtual "Folie à Trois". (PubMed, Consort Psychiatr) - "This case underscores that psychological proximity fostered through immersive digital platforms may suffice for the transmission of delusional beliefs. Clinicians must routinely explore virtual relationships and digital group identities as potential vectors of psycho-pathology. Early detection, digital boundary setting, and integrative therapy approaches are essential in managing such emerging presentations."

Journal • CNS Disorders • Insomnia • Psychiatry • Sleep Disorder

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. (PubMed, BMJ Ment Health) - "There is currently not enough evidence to guide the prescription of statins for psychiatric symptom improvement in patients with SMI. If there is an effect of statins, it may be through specific statin-antipsychotic combinations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Delayed onset of striatal projection neuron hyperexcitability in Fmr1-/y mice. (PubMed, Front Cell Neurosci) - "Chronic aripiprazole treatment, a widely prescribed therapy for behavioral symptoms in FXS, fails to normalize SPN excitability, suggesting limited efficacy in addressing core SPN dysfunction. These findings reveal that DMS SPN hyperexcitability in Fmr1-/y mice emerges after early postnatal development, pointing to a progressive trajectory of striatal abnormalities. In addition, these results underscore the importance of developmental timing in FXS pathophysiology and emphasize the need for targeted interventions to address SPN dysfunction."

Journal • Preclinical • Autism Spectrum Disorder • Developmental Disorders • Fragile X Syndrome • Genetic Disorders • Mental Retardation • FMR1

Association of propranolol with treatment-emergent akathisia during aripiprazole treatment. (PubMed, Ideggyogy Sz) - "The objective of the present retrospective study was to assess the prevalence of akathisia in patients receiving propranolol or metoprolol comedication, as well as in those not receiving any CYP2D6 inhibitors such as propranolol, metoprolol, risperidone. However, two major limitations should be considered: akathisia was not assessed using a standardized clinical rating scale, and the majority of patients (80.6%) received antipsychotic combination therapy, which may have influenced the findings. Further prospective studies are needed to confirm these findings based on retrospective, naturalistic analysis about the development of aripiprazole-induced akathisia."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Managing Symptoms in Adolescent-Onset Schizophrenia: A Narrative Review of Therapeutic Interventions. (PubMed, Healthcare (Basel)) - "Synthesis of this evidence highlights atypical antipsychotics such as aripiprazole and brexpiprazole as well-tolerated first-line options for positive symptom reduction, while clozapine remains the most effective treatment for resistant AOS. High-dose olanzapine offers comparable efficacy but carries greater metabolic risk...Collectively, these findings highlight the importance of early, developmentally informed, and multidisciplinary interventions tailored to adolescents. Strengthening longitudinal, biomarker-guided, and neuromodulation-inclusive studies will be critical for refining precision treatment models and informing future clinical and policy frameworks for adolescent psychosis care."

Journal • Review • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia • CCL11 • IL6

Antioxidant Supplementation with ProCloSupp Protects Against Renal Toxicity of Atypical Antipsychotics in Rats: Implications for Safer Treatment Strategies. (PubMed, Life (Basel)) - "Atypical antipsychotics (AAP), including clozapine (Clo), aripiprazole (Ari), and risperidone (Ris), are widely used in psychiatry but can lead to kidney damage due to oxidative stress. In conclusion, subchronic Clo, Ari, and Ris exposure induces oxidative renal damage in rats, while PCS supplementation enhances antioxidant defences and attenuates tissue damage. These results support PCS as a potential nephroprotective strategy in antipsychotic therapy."

Journal • Preclinical • CNS Disorders • Psychiatry • CAT

Review of Autism Spectrum Disorder (ASD): Epidemiology, Aetiology, Pathology, and Pharmacological Treatment. (PubMed, Pharmaceuticals (Basel)) - "Atypical antipsychotics (AAPs), particularly risperidone and aripiprazole, provide superiority over other drug classes of pharmacological interventions. These ADRs may lead to chronic diseases such as diabetes and cardiovascular conditions, adding strain to healthcare systems beyond the original treatment of ASD. This narrative review enhances our understanding of ASD and highlights a gap in current knowledge about the evaluation of the effectiveness and safety of pharmacological treatments, especially AAPs for ASD in paediatric patients."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Cardiovascular • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Pediatrics • Psychiatry

Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine and Risperidone in Alzheimer's Disease: A Real□World Cohort Study with Treatment Effect Heterogeneity Analysis. (PubMed, medRxiv) - "Aripiprazole and quetiapine were associated with lower mortality compared to olanzapine and risperidone. Treatment effect heterogeneity suggests the need for individualized prescribing based on patient characteristics such as comorbid T2DM."

Heterogeneity • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: All India Institute of Medical Sciences, Bhubaneswar | Recruiting ➔ Completed

Trial completion • CNS Disorders • Metabolic Disorders • Psychiatry • Schizophrenia

Magnetic Seizure Therapy for Psychotic Disorders (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Epilepsy • Psychiatry

Clinical outcomes and serum prolactin levels in patients with antipsychotic-induced hyperprolactinemia following different management strategies. (PubMed, Int J Psychiatry Clin Pract) - "Patients were assigned to four management groups: watchful waiting, dose reduction, switching and adjunctive treatment (with aripiprazole)...No significant changes were observed in sexual dysfunction, hirsutism or acne. Management strategies for antipsychotic-induced hyperprolactinaemia, particularly switching or adjunctive treatments, effectively reduce prolactin levels and improve related symptoms."

Clinical data • Journal • Acne Vulgaris • CNS Disorders • Sexual Disorders • Women's Health • PRL

Aripiprazole in the treatment of psychiatric disorders in childhood (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Aripiprazole is also included in national clinical guidelines for the treatment of autistic disorders. The high frequency of prescribing aripiprazole in childhood is due not only to its positive effect on negative, cognitive and affective symptoms, but also to its good general tolerance, low probability of developing extrapyramidal symptoms, absence of adverse effects on body weight and metabolic parameters (lipid profile, tissue sensitivity to insulin, etc.)."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Genetic Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Schizophrenia

Low-dose intravenous esketamine on a depressive catatonia patient with venous thromboembolism: a case report. (PubMed, Front Psychiatry) - "Benzodiazepines, aripiprazole and nutritional support were given after admission...With the consent of her and family, we decied to administrate a sub-anesthetic dose of intravenous (IV) Esketamine (0.2 mg/Kg) combined with 50mg desvenlafaxine...As a safe and rapid intervention, Esketamine might be a new option for catatonic patients who cannot undergo MECT or fail to respond to conventional treatment. It may be worthy of further research in the future."

Journal • Anesthesia • Cardiovascular • CNS Disorders • Depression • Hematological Disorders • Major Depressive Disorder • Mood Disorders • Psychiatry • Thrombosis • Venous Thromboembolism

Catalase Gene Variants and Oxidative Stress in Autism Spectrum Disorder: A Northern Lebanon Cohort and Aripiprazole In Vitro Toxicity. (PubMed, Int J Dev Neurosci) - "CAT polymorphism rs7943316 is not associated with ASD in this population. However, aripiprazole exerts dose-dependent toxicity strongly modulated by oxidative stress and metabolic pathways. These findings support the integration of genetic and toxicological approaches for understanding ASD and optimizing therapeutic safety."

Journal • Preclinical • Autism Spectrum Disorder • Genetic Disorders • Metabolic Disorders • CAT

Comparative Efficacy and Tolerability of Multiple Antipsychotics Across Varying Doses for Neuropsychiatric Symptoms of Dementia Including Alzheimer's Disease: A Dose-Response Model-Based Network Meta-Analysis. (PubMed, Acta Psychiatr Scand) - "Aripiprazole 10 mg, brexpiprazole 1-2.5 mg, risperidone 1 mg, and olanzapine 2.5 mg were both effective and well tolerated, indicating their potential as favorable treatment options. As the present model incorporates several sources of uncertainty, its findings should be interpreted with caution and regarded as a provisional framework to support clinical decision-making."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia • Psychiatry

Fatal atomoxetine overdose in Japan: a forensic autopsy case report. (PubMed, Int J Legal Med) - "Cardiac blood screening, performed using a semi-quantitative analysis, detected 7-aminoflunitrazepam, 7-aminonitrazepam, allylisopropylacetylurea, aripiprazole, atomoxetine, bromazepam, and suvorexant. The atomoxetine and bromazepam concentrations were 23.2 and 0.71 µg/mL in femoral blood and 24.0 and 0.78 µg/mL in cardiac blood. In conclusion, the cause of death was primarily due to acute atomoxetine intoxication, with bromazepam excluded as a direct contributing factor."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry